SCHEDULE 13G: BlackRock Discloses 9.9% Passive Stake in Rigel Pharmaceuticals

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 9.9% of Rigel Pharmaceuticals Inc.'s common stock as of December 31, 2024.

Summary

• BlackRock, Inc. reported beneficial ownership of 1,748,107 shares of Rigel Pharmaceuticals Inc. common stock.
• This stake represents 9.9% of the total outstanding common stock of Rigel Pharmaceuticals Inc.
• The filing was made under Rule 13d-1(b), indicating BlackRock is a qualified institutional investor holding the shares in the ordinary course of business without intent to influence control.
• BlackRock holds sole voting power over 1,690,163 shares and sole dispositive power over 1,748,107 shares.
• The ownership is aggregated across various BlackRock business units, including BlackRock Advisors, LLC, Aperio Group, LLC, BlackRock Asset Management Canada Limited, BlackRock Fund Advisors, BlackRock Asset Management Ireland Limited, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., BlackRock Japan Co., Ltd., and BlackRock Investment Management, LLC.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing reporting beneficial ownership. It does not contain positive or negative performance indicators or forward-looking statements that would influence sentiment beyond neutrality.

Future Outlook

NA

Management Comments

• BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors like BlackRock, indicating a significant passive ownership stake (5% or more) in a publicly traded company. This filing reflects BlackRock's role as a major asset manager, holding shares across numerous companies for its clients, typically without seeking to influence corporate control. Such filings provide transparency into large institutional holdings, which can be a signal of investor confidence or simply a reflection of broad market index tracking.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for institutional investors exceeding a 5% ownership threshold.
• BlackRock, as one of the world's largest asset managers, routinely files Schedule 13Gs for its passive holdings across a vast portfolio of companies.
• The 9.9% stake in Rigel Pharmaceuticals Inc. is consistent with the diversified investment strategies of large institutional funds, which often include significant positions in biotechnology or pharmaceutical companies like Rigel.
• There are no specific comparable companies or projects mentioned in this filing to assess results against industry benchmarks, as it is purely an ownership disclosure.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can be viewed as a vote of confidence by a major asset manager, though it's a passive holding.
• Company Management: Awareness of a large, passive institutional holder, which typically does not seek to influence control.

Key Dates

Keywords

SEC filing, Schedule 13G, beneficial ownership, Rigel Pharmaceuticals Inc., BlackRock Inc., institutional investor, common stock, passive investment